JP2024536362A - 放射標識化された線維芽細胞活性化タンパク質リガンド - Google Patents
放射標識化された線維芽細胞活性化タンパク質リガンド Download PDFInfo
- Publication number
- JP2024536362A JP2024536362A JP2024520693A JP2024520693A JP2024536362A JP 2024536362 A JP2024536362 A JP 2024536362A JP 2024520693 A JP2024520693 A JP 2024520693A JP 2024520693 A JP2024520693 A JP 2024520693A JP 2024536362 A JP2024536362 A JP 2024536362A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- independently
- alkylene
- cooh
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/06—Aluminium compounds
- C07F5/069—Aluminium compounds without C-aluminium linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21200719 | 2021-10-04 | ||
| EP21200719.9 | 2021-10-04 | ||
| EP22151771.7 | 2022-01-17 | ||
| EP22151771 | 2022-01-17 | ||
| PCT/EP2022/077598 WO2023057457A1 (en) | 2021-10-04 | 2022-10-04 | Radiolabelled fibroblast activation protein ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536362A true JP2024536362A (ja) | 2024-10-04 |
| JP2024536362A5 JP2024536362A5 (enExample) | 2025-10-15 |
Family
ID=84330437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520693A Pending JP2024536362A (ja) | 2021-10-04 | 2022-10-04 | 放射標識化された線維芽細胞活性化タンパク質リガンド |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4412996A1 (enExample) |
| JP (1) | JP2024536362A (enExample) |
| KR (1) | KR20240093543A (enExample) |
| AU (1) | AU2022358921A1 (enExample) |
| CA (1) | CA3234394A1 (enExample) |
| IL (1) | IL311694A (enExample) |
| MX (1) | MX2024004077A (enExample) |
| WO (1) | WO2023057457A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| KR20250073273A (ko) * | 2022-09-23 | 2025-05-27 | 누클리디움 아게 | 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도 |
| CN120957982A (zh) | 2023-05-08 | 2025-11-14 | 江苏恒瑞医药股份有限公司 | 靶向成纤维细胞活化蛋白的配体 |
| CN116925041B (zh) * | 2023-06-12 | 2024-12-24 | 上海交通大学医学院附属仁济医院 | 靶向成纤维细胞激活蛋白的氟标记放射性药物前体、放射性标记化合物及其应用 |
| CN120136958A (zh) * | 2023-12-13 | 2025-06-13 | 无锡诺宇医药科技有限公司 | Fap靶向放射性药物 |
| WO2025167951A1 (zh) * | 2024-02-07 | 2025-08-14 | 苏州博锐创合医药有限公司 | 一种成纤维细胞活化蛋白抑制剂 |
| TW202600606A (zh) * | 2024-02-21 | 2026-01-01 | 美商雅博得樂醫療公司 | 抗體連接子結合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005087235A1 (en) | 2004-03-09 | 2005-09-22 | National Health Research Institutes | Pyrrolidine compounds |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| EA202090776A1 (ru) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| US11780821B2 (en) | 2017-12-15 | 2023-10-10 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| EP3749663A1 (en) | 2018-02-06 | 2020-12-16 | Universität Heidelberg | Fap inhibitor |
| WO2019154859A1 (en) | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| EP4019507A1 (en) * | 2020-02-12 | 2022-06-29 | Philochem AG | Fibroblast activation protein ligands for targeted delivery applications |
-
2022
- 2022-10-04 KR KR1020247015053A patent/KR20240093543A/ko active Pending
- 2022-10-04 MX MX2024004077A patent/MX2024004077A/es unknown
- 2022-10-04 WO PCT/EP2022/077598 patent/WO2023057457A1/en not_active Ceased
- 2022-10-04 JP JP2024520693A patent/JP2024536362A/ja active Pending
- 2022-10-04 CA CA3234394A patent/CA3234394A1/en active Pending
- 2022-10-04 IL IL311694A patent/IL311694A/en unknown
- 2022-10-04 AU AU2022358921A patent/AU2022358921A1/en active Pending
- 2022-10-04 EP EP22801357.9A patent/EP4412996A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240093543A (ko) | 2024-06-24 |
| AU2022358921A1 (en) | 2024-05-02 |
| IL311694A (en) | 2024-05-01 |
| CA3234394A1 (en) | 2023-04-13 |
| EP4412996A1 (en) | 2024-08-14 |
| MX2024004077A (es) | 2024-04-18 |
| WO2023057457A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024536362A (ja) | 放射標識化された線維芽細胞活性化タンパク質リガンド | |
| TWI657827B (zh) | 用於正子斷層掃描之化合物 | |
| CN111263747B (zh) | 双官能螯合物的药代动力学增强及其用途 | |
| US20240148916A1 (en) | Bivalent fibroblast activation protein ligands for targeted delivery applications | |
| JP7641050B2 (ja) | 繊維芽細胞活性化タンパク質阻害剤 | |
| CN118955616B (zh) | 一种靶向结合成纤维细胞活化蛋白化合物及应用 | |
| JP7646637B2 (ja) | 画像化及び治療用組成物 | |
| JP2025503451A (ja) | 炭酸脱水酵素ｉｘリガンド | |
| JP2026500913A (ja) | ソマトスタチンサブタイプ－２受容体（ｓｓｔ２ｒ）標的化治療薬及びその使用 | |
| CN116917278A (zh) | 用于靶向递送应用的二价成纤维细胞活化蛋白配体 | |
| EP4043452A1 (en) | Bivalent fibroblast activation protein ligands for targeted delivery applications | |
| JP2026508513A (ja) | 窒素含有複素環系化合物およびその製造方法と使用 | |
| CN118234720A (zh) | 放射性标记的成纤维细胞激活蛋白配体 | |
| JP2024516797A (ja) | 葉酸受容体標的化放射線治療剤及びそれらの使用 | |
| Singh et al. | A homodimeric bivalent radioligand derived from 1-(2-methoxyphenyl) piperazine with high affinity for in vivo 5-HT1A receptor imaging | |
| JP2025540658A (ja) | 神経ペプチドｙ１受容体（ｎｐｙ１ｒ）を標的とした治療薬およびその使用 | |
| BR112023015831B1 (pt) | Ligantes de proteína de ativação de fibroblastos bivalentes para aplicações de liberação direcionada, composições farmacêuticas, seus usos e métodos para preparar um conjugado | |
| TW202535356A (zh) | 神經肽y1受體(npy1r)靶向治療劑及其用途 | |
| WO2025088200A2 (en) | Acid phosphatase 3 ligands for targeted delivery applications | |
| AU2024365851A1 (en) | Acid phosphatase 3 ligands for targeted delivery applications | |
| HK40127186A (zh) | 成纤维细胞激活蛋白(fap)抑制剂、fap缀合物及其诊断和治疗用途 | |
| CN120590466A (zh) | 一种靶向成纤维细胞活化蛋白的化合物及其应用 | |
| HK40019820A (en) | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251006 |